Cardiovascular System
Boji Pharmaceuticals is deeply committed to the cardiovascular and cerebrovascular fields, focusing on pulmonary arterial hypertension, heart failure, hypertension, and coronary heart disease. The company conducts systematic clinical research and develops innovative drugs.
INTRODUCTION
In the field of cardiovascular disease research and innovative therapies, Boji Pharmaceuticals demonstrates profound professional expertise and forward-thinking scientific vision, focusing on systematic exploration of treatments for major cardiovascular conditions including pulmonary arterial hypertension, heart failure, hypertension, and coronary heart disease.
Our specialized team actively engages in clinical research and new drug development for these diseases, committed to integrating traditional cardiovascular treatment concepts with cutting-edge modern medical technologies. Whether enhancing the safety and efficacy of existing therapies or advancing the clinical translation of innovative drugs and treatment models, Boji Pharmaceuticals consistently prioritizes patient-centered care. We strive to slow disease progression, improve quality of life, and reduce the risk of cardiovascular events. Through continuous scientific dedication and persistent breakthroughs in technical barriers, we provide scientific, precise, and accessible solutions for the prevention, treatment, and rehabilitation of cardiovascular and cerebrovascular diseases.
Clinical Research Project Experience
- Pulmonary Hypertension
- Heart failure
- Hypertension
- Coronary heart disease
PROJECT EXPERIENCE
Assisting Sanqi Tongshu Capsules in Successfully Securing China's First Class II Protection for Traditional Chinese Medicine
Sanqi Tongshu Capsules, originally classified as a Category II new traditional Chinese medicine, is a formulation derived from the active component (Panax notoginsenoside) of Panax notoginseng that promotes blood circulation and removes blood stasis. As a new-generation Panax notoginseng preparation, it exhibits multiple therapeutic effects including antiplatelet aggregation, prevention of thrombus formation, improvement of cerebral ischemia, and promotion of neurological function recovery. It has now developed into a major traditional Chinese medicine product for treating cardiovascular and cerebrovascular diseases. Boji Pharmaceutical provided CRO services for the traditional Chinese medicine protection variety of this drug.